Disclaimer: You are now leaving www.beiresources.org and are going to a website that is not operated by BEI Resources. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE: BEI Resources offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the BEI Resources website and will be redirected to another site. These sites are not under the control of BEI Resources. BEI Resources is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than BEI Resources policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
Are you sure you would like to be notified when the item is available?
For research use only. Not for use in humans.
BEI Resources
Note: Environmental and clinical isolates of P. aeruginosa frequently contain viruses known as prophages. During growth, some strains from the Pseudomonas aeruginosa Diversity Panel displayed plaques resulting from the activation of their inherent prophages. Please refer to the Certificate of Analysis to determine if phage plaques were observed for this strain.
P. aeruginosa is a Gram-negative, aerobic, rod-shaped bacterium with unipolar motility that thrives in many diverse environments including soil, water and certain eukaryotic hosts. It is a key emerging opportunistic pathogen in animals, including humans and plants. While it rarely infects healthy individuals, P. aeruginosa causes severe acute and chronic nosocomial infections in immunocompromised or catheterized patients, especially in patients with cystic fibrosis, burns, cancer or HIV. Infections of this type are often highly antibiotic resistant, difficult to eradicate and often lead to death. The ability of P. aeruginosa to survive on minimal nutritional requirements, tolerate a variety of physical conditions and rapidly develop resistance during the course of therapy has allowed it to persist in both community and hospital settings.
Media:
Tryptic Soy broth or Brain Heart Infusion broth or Nutrient broth or equivalent
Tryptic Soy agar with 5% defibrinated sheep blood or Brain Heart Infusion agar or Nutrient agar or equivalent
Incubation:
Temperature: 37°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 1 day.
You are authorized to use this product for research use only. It is not intended for human use.
Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.
While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.
1. McGann, P., Personal Communication.
2. Tsao, Y.-F., et al. “Phage Morons Play an Important Role in Pseudomonas aeruginosa Phenotypes.” J. Bacteriol. 200 (2018): e00189-18. PubMed: 30150232.
3. Silva Filho, L. V., et al. “Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis: Scientific Evidence Regarding Clinical Impact, Diagnosis, and Treatment.” J. Bras. Pneumol. 39 (2013): 495-512. PubMed: 24068273.
4. Dettman, J. R., et al. “Evolutionary Genomics of Epidemic and Nonepidemic Strains of Pseudomonas aeruginosa.” Proc. Natl. Acad. Sci. USA 110 (2013): 21065-21070. PubMed: 24324153.
5. Morita, Y., J. Tomida and Y. Kawamura. “Responses of Pseudomonas aeruginosa to Antimicrobials.” Front. Microbiol. 4 (2014): 422. PubMed: 24409175.
6. Lister, P. D., D. J. Wolter and N. D. Hanson. “Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms.” Clin. Microbiol. Rev. 22 (2009): 582-610. PubMed: 19822890.
When applying for permits and forms please:
Do NOT reference BEI Resources or ATCC Catalog Numbers in the Material Description fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly as they appear on your BEI Resources registration.
Information about permits is provided as a courtesy to BEI Resources customers. While we use reasonable efforts to include accurate and up-to-date information on this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the biological materials provided by BEI Resources, please select this link: Compliance Requirements.